Media Articles Related to Nicotrol NS (Nicotine Nasal)
Smoking cessation drug not boosting number of smokers who quit
Source: Smoking / Quit Smoking News From Medical News Today [2015.08.18]
The introduction of a new prescription smoking-cessation aid, varenicline, in 2006 has had no significant impact on the rate at which Americans age 18 and older successfully quit smoking, according...
Quitting Smoking After MI Lowers Angina Risk, Ups Well-being
Source: theheart.org | Medscape Cardiology Headlines [2015.08.27]
"Smoking cessation not only reduces the risk of MI and death but is also associated with better health status, [which] may offer current smokers increased . . . motivation for quitting," a new study reports.
Heartwire from Medscape
Published Studies Related to Nicotrol NS (Nicotine Nasal)
Nicotine nasal spray as an adjuvant analgesic for third molar surgery. [2011.05]
PURPOSE: To determine the efficacy of preoperatively administered nicotine nasal spray (3 mg) for analgesia after third molar (TM) surgery... CONCLUSION: Pain is well controlled by hydrocodone/acetaminophen in most patients after TM surgery. However, there is significant variability in pain reported. Nicotinic agonists represent a new class of analgesic that can be considered for patients who are expected to have significant opioid-resistant pain after TM surgery. Caution should be used with patients in whom a small increase in heart rate would be deleterious. Copyright (c) 2011 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.
Direction and magnitude of nicotine effects on the fMRI BOLD response are related to nicotine effects on behavioral performance. [2011.05]
Considerable variability across individuals has been reported in both the behavioral and fMRI blood oxygen level-dependent (BOLD) response to nicotine. We aimed to investigate (1) whether there is a heterogeneous effect of nicotine on behavioral and BOLD responses across participants and (2) if heterogeneous BOLD responses are associated with behavioral performance measures...
Treating heavy smokers in primary care with the nicotine nasal spray: randomized placebo-controlled trial. [2011.04]
AIMS: Of six established nicotine replacement therapy (NRT) formulations, only the gum and patch have been tested without specialist clinic support in placebo-controlled trials. We aimed to broaden the evidence base by examining if the nicotine nasal spray (NNS) could be effective with only brief support in general practice... CONCLUSIONS: NNS is effective when given in primary care. The benefit was lower than in a specialist clinic but similar to that with the nicotine patch in primary care. Unlike most other NRT formulations, bupropion or varenicline, NNS was especially helpful for more dependent smokers. Continuing treatment of those initially failing was not beneficial. An initial 1-week prescription to those more dependent on nicotine is likely to be the most cost-effective NNS treatment protocol. These results should offer support to the effectiveness of the other NRT formulations untested in this setting. (c) 2011 The Authors, Addiction (c) 2011 Society for the Study of Addiction.
Treating heavy smokers in primary care with the nicotine nasal spray: randomized
placebo-controlled trial. 
general practice... CONCLUSIONS: NNS is effective when given in primary care. The benefit was lower
Effects of nicotine patch or nasal spray on nicotine and cotinine concentrations in pregnant smokers. [2009.09]
OBJECTIVE: To examine the short-term effects of the nicotine patch or nasal spray on measures of nicotine exposure, withdrawal symptoms, and on maternal and fetal heart rates in pregnant smokers... CONCLUSIONS: Nicotine patch and nasal spray reduce maternal nicotine exposure compared with smoking and may be effective for smoking cessation.
Clinical Trials Related to Nicotrol NS (Nicotine Nasal)
Pilot Pharmacokinetic Study of Investigational Sublingual Nicotine Tablet Versus COMMIT Nicotine Lozenge [Completed]
The objective of this study is to compare the pharmacokinetics of an investigational 2 mg
sublingual nicotine tablet (Pharmaceutical Productions Inc.) to a 2 mg Commit® nicotine
lozenge (GlaxoSmith Kline) in a randomized crossover design in 6 male and female otherwise
Neural Mechanisms Underlying Nicotine and Alcohol Combinations [Active, not recruiting]
Nicotine and alcohol are frequently used together and their combined use contributes to more
than half a million deaths each year, with more alcoholics dying from smoking-related
diseases than from alcohol-related diseases. Using a new multi-modal MRI approach combined
with data fusion, the investigators propose to study how nicotine modulates alcohol-induced
changes in the function of brain circuits. The investigators hypotheses are:
- functional connectivity (FC) in the reward network, containing components of the
mesolimbic dopamine system, will be altered by alcohol, and additional increases in FC
will be observed if nicotine is also present (e. g., additive effects).
- co-administration of nicotine will counteract the effects of alcohol on FC in multiple
brain networks, including visual, sensorimotor and motor brain circuits, that may be
associated with the impairing effects of alcohol
Comparison of Pharmacokinetic Profiles of Two Nicotine Gum Formulations [Completed]
The primary objective of this study is to compare pharmacokinetic (PK) profiles and assess
the bioequivalence between the newly developed nicotine gums (2 mg and 4 mg) and the
reference nicotine gums (2 mg and 4 mg) in healthy smokers.
Nicotine Vaccination and Nicotinic Receptor Occupancy [Completed]
This is a molecular imaging research study designed to examine how much nicotine gets into
the brain before and after vaccination with NicVAX, a nicotine vaccine developed by Nabi
Biopharmaceuticals. NicVAX (Nicotine Conjugate Vaccine) is an investigational vaccine
designed as an aid to smoking cessation and long-term abstinence, as well as an aid to
prevent relapses of a treated smoker.
In this project we want to understand the degree to which NicVAX administration changes how
much nicotine enters the brain in smokers.
Concurrent Bupropion / Varenicline for Smoking Cessation [Completed]
This study focuses on the first step in developing an algorithm for maximizing quit-smoking
success based on an adaptive approach, which changes treatment from the initial nicotine
replacement therapy (NRT) when that treatment alone may not be sufficient. These NRT
"non-responders" are switched (in double-blind fashion) before the quit date to receive
either varenicline alone or varenicline paired with bupropion. Some participants who would
otherwise have failed at their quit smoking attempt could be "rescued" by switching to
alternative pharmacotherapies. The proposed study will evaluate the combination treatment
against varenicline alone in an adaptive trial design